A Phase 1 interventional study of KUP-101A in Cutaneous Melanoma, Mucosal Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC), sponsored by Kupando GmbH. Recruiting at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Kupando GmbH · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Melanoma with a site in Germany — 37 open to participants now, 70 under way, 20 of them phase 3. Melanoma · Germany.
Among the 284 studies in Melanoma with a site in Germany, this one is the 213th largest by planned enrollment of the 249 interventional ones that give a count, is one of 8 that started in 2026, is one of 36 in phase 1, reaches primary completion later than 59 of the 69 other live ones, and was the 280th registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →37 of the 284 studies in Melanoma with a site in Germany are open now. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18+
Bristol-Myers Squibb · Sites in Germany, United States, Belgium and 10 more countries
Ages 18+
Wuerzburg University Hospital · Sites in Germany
Ages 18+
Mitra Bio · Sites in Germany, Belgium, Spain and 1 more country
Ages 18+
University of Regensburg · Sites in Germany
Ages 18+ · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 78 · Phase 2 124 · Phase 3 75 · Phase 4 3
First in 1995; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 21 is below the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 162 across the 249 interventional studies, 420 across the 32 observational. Of the 183 that completed or were terminated, 90 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
202 of 284 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Kupando GmbH as lead sponsor.
Kupando GmbH has 1 study filed under Melanoma — fewer than ten, so there is no comparison to draw.
20 of the studies in Melanoma with a site in Germany that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT05270044Phase 3Pierre Fabre MedicamentAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | 2027-03-31 |
| NCT04309409Phase 3University Hospital, EssenAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma | 2027-09 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 20 to your calendar (.ics) → With an account.
Among the 284 studies in Melanoma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: KUP-101A
Drug: KUP-101A
Drug: KUP-101A
Drug: KUP-101A
Drug: KUP-101A
Drug: KUP-101A
Drug: KUP-101A
Intravenous infusion of KUP-101A
Proportion of patients with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and related TEAEs
Time frame: From enrollment until three months after last dose administration
Proportion of patients with dose-limiting toxicities (DLTs)
Time frame: From start of treatment until one week after last dose administration.
Incidence of laboratory abnormalities, based on hematology, clinical chemistry, and urinalysis test results
Time frame: From enrollment until three months after last dose administration
Incidence of abnormal clinical findings in 12-lead ECG parameters and vital signs
Time frame: From enrollment until three months after last dose administration
Area Under the Concentration time Curve from Time 0 Extrapolated to Infinity
Time frame: up to 3 weeks
Maximum Observed Concentration
Time frame: up to 3 weeks
Time of the maximum observed concentration
Time frame: up to 3 weeks
Apparent terminal elimination half-life
Time frame: up to 3 weeks
Change from baseline in cytokine levels
Time frame: From enrollment until three months after last dose administration
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.
Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's planned 29 months is below that.
Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.